Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $26.7 million.

  • Janux Therapeutics' Non-Current Assets fell 703.18% to $26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.6 million, marking a year-over-year decrease of 922.07%. This contributed to the annual value of $27.8 million for FY2024, which is 1063.98% down from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Non-Current Assets is $26.7 million, which was down 703.18% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Non-Current Assets ranged from a high of $32.2 million in Q2 2023 and a low of $215000.0 during Q2 2021
  • In the last 5 years, Janux Therapeutics' Non-Current Assets had a median value of $28.3 million in 2024 and averaged $23.5 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 1259767.44% in 2022, then crashed by 1063.98% in 2024.
  • Over the past 5 years, Janux Therapeutics' Non-Current Assets (Quarter) stood at $2.8 million in 2021, then soared by 1025.53% to $31.6 million in 2022, then fell by 1.28% to $31.2 million in 2023, then fell by 10.64% to $27.8 million in 2024, then dropped by 4.2% to $26.7 million in 2025.
  • Its Non-Current Assets stands at $26.7 million for Q3 2025, versus $26.7 million for Q2 2025 and $27.4 million for Q1 2025.